Introduction {#Sec1}
============

Heparanase is an endo-β-glucuronidase that cleaves highly potent heparan sulfate (HS) from its proteoglycan, thereby triggering the inflammatory response in \[[@CR1]\]. Thus, new anti-infective agents that interact with heparanase may be promising tools for sepsis therapy. As a novel anti-infective agent, peptide 19-2.5 (pep2.5) belongs to the class of synthetic anti-lipopolysaccharide peptides, however its activity is not restricted to Gram-negative bacterial infection \[[@CR2], [@CR3]\].

Objectives {#Sec2}
==========

To evaluate the interaction of pep2.5 with heparanase in murine sepsis *in vivo* and in human sepsis *ex vivo*.

Methods {#Sec3}
=======

First, we used a model of murine cecal ligature and puncture (CLP) sepsis to study the impact of pep2.5 on heparanase *in vivo* in 12 NMRI mice. Mice were treated with pep2.5 or NaCl 0.9%. Plasma was sampled 24h after CLP. Second, we investigated whether pep2.5 interacts with heparanase in human plasma samples *ex vivo*. We added pep2.5 (20µg/ml) to plasma of 18 septic shock patients according to the ACCP/SCCM definitions and to plasma of 10 healthy volunteers. Heparanase-levels, HS-levels and heparanase activity were measured using ELISA (AMS Biotechnology, Oxon, United Kingdom). All data are given as mean ± standard deviation. a t-test with Holm-Šídák correction was used and a p-value \< 0.05 was considered significant.

Results {#Sec4}
=======

Mice subjected to CLP without treatment displayed higher heparanase levels in plasma compared to mice treated with pep2.5 (p \< 0.0001). Treatment with pep2.5 resulted in lower heparanase activity (p \< 0.0001) and reduced HS-levels (p \< 0.0001), compared to untreated animals (Figure [1](#Fig1){ref-type="fig"}).Figure 1(**A**) Heparanase level in CLP-mice. (**B**) Heparanase level in human.\*p \< 0.05, \*\*p \< 0.005, \*\*\*p \< 0.001.

Septic shock patients (78% male) were 70 ± 15 years old and healthy volunteers (50% male) were 67 ± 19 years old. Plasma heparanase levels, heparanase activity and HS-levels were significantly higher in individuals with septic shock than in healthy individuals (all p \< 0.0001). the *ex vivo* addition of pep2.5 did not impact heparanase levels, however heparanase activity and HS-levels were decreased by adding pep2.5 to plasma of septic shock patients (all p \< 0.05, Figure [1](#Fig1){ref-type="fig"}).

Conclusions {#Sec5}
===========

The synthetic antimicrobial peptide 19-2.5 interacts with heparanase in human and murine sepsis and reduces levels of highly potent HS. Thus, peptide 19-2.5 may have the potential for further development as a new anti-infective drug in sepsis therapy.
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